Evolus Reports Q3 2026 Financial Results
Evolus, Inc. announced its third-quarter 2026 financial results, highlighting 13% revenue growth and a fourth consecutive quarter of positive adjusted EBITDA.
Stocks · News reference
Reported Earlier, Telix Names David Gill Board Chair As Mark Nelson Steps Down From Interim Role
Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, "Telix" or the "Company") today announces that David Gill has been appointed Chair of the Board, effective immediately.Mr. Gill joined Telix as a
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
BTIG Raises Price Target on Evolus to $15
BTIG maintained its 'Buy' rating on Evolus, Inc. and increased its price target from $13 to $15.
8-K filing — Evolus, Inc. (EOLS)
Filed: 2026-11-04 AccNo: 0001628280-26-070150 Size: 408 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
HDI Seguros Completes Integration of Sompo Life Insurance Portfolio onto insureMO Platform
HDI Seguros, a subsidiary of Talanx, has successfully migrated its life insurance portfolio acquired from Sompo onto the insureMO insurance middle office platform.
Evolus Management to Participate in Upcoming Investor Conferences
Evolus, Inc. announced that its management team will participate in investor conferences in New York and London in November 2026.
Wedbush Reiterates Outperform on Telix Pharmaceuticals, Maintains $22 Price Target